GlassScriptPhysician profile
Aly El-Hag
NPI 1023212859
$2,238.30
in general payments reported to CMS, 2019-2025
15 companies · $595 in 2025
The $595 reported for 2025 was more than what 82% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $251 · 2020: $61.07 · 2021: $206 · 2022: $320 · 2023: $362 · 2024: $445 · 2025: $595.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,401.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,400.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $999.38 | 2019-2025 | Tezspire, Airsupra |
| Regeneron Healthcare Solutions, INC. | $390.63 | 2022-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $219.09 | 2020-2025 | |
| Glaxosmithkline, LLC. | $123.46 | 2019-2023 | Nucala, Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $111.88 | 2022-2025 | Gamunex-C, Xembify |
| Csl Behring | $105.61 | 2024 | Haegarda |
| Genzyme Corporation | $64.00 | 2019-2021 | |
| Alexion Pharmaceuticals, INC. | $49.74 | 2025 | Ultomiris |
| Kedrion Biopharma, INC. | $45.55 | 2025 | Kedrab, Gammaked, Koate |
| Teva Pharmaceuticals USA, INC. | $29.27 | 2022 | |
| Shire North American Group INC | $28.65 | 2019 | |
| Organon LLC | $20.22 | 2025 | |
| Azurity Pharmaceuticals, INC. | $19.26 | 2025 | Alvesco |
| Hikma Pharmaceuticals USA | $17.18 | 2023 | Ryaltris |
| Takeda Pharmaceuticals U.S.A., INC. | $14.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aly El-Hag listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.